127 related articles for article (PubMed ID: 38680990)
1. A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer.
Juarez TM; Gill JM; Heng A; Carrillo JA; Wagle N; Nomura N; Nguyen M; Truong J; Dobrawa L; Sivakumar W; Barkhoudarian G; Kelly DF; Kesari S
Neurooncol Adv; 2024; 6(1):vdae049. PubMed ID: 38680990
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
3. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
[TBL] [Abstract][Full Text] [Related]
4. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
Marshall J; Hwang J; Eskens FA; Burger H; Malik S; Uttenreuther-Fischer M; Stopfer P; Ould-Kaci M; Cohen RB; Lewis NL
Invest New Drugs; 2013 Apr; 31(2):399-408. PubMed ID: 23161335
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.
Camidge DR; Sequist LV; Jänne PA; Weickhardt AJ; Dowling ES; Alicea J; Fan J; Oxnard GR
Clin Lung Cancer; 2018 Sep; 19(5):e655-e665. PubMed ID: 29861396
[TBL] [Abstract][Full Text] [Related]
7. Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial.
Geoerger B; Marshall LV; Nysom K; Makin G; Bouffet E; Defachelles AS; Amoroso L; Aerts I; Leblond P; Barahona P; Van-Vlerken K; Fu E; Solca F; Lorence RM; Ziegler DS
Eur J Cancer; 2023 Jul; 188():8-19. PubMed ID: 37178647
[TBL] [Abstract][Full Text] [Related]
8. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD;
Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Kuyama S; Kudo K; Bessho A; Fukamatsu N; Fujimoto N; Aoe K; Shibayama T; Sugimoto K; Takigawa N; Hotta K; Kiura K
Lung Cancer; 2018 Jan; 115():103-108. PubMed ID: 29290249
[TBL] [Abstract][Full Text] [Related]
10. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
Park JS; Hong MH; Chun YJ; Kim HR; Cho BC
Lung Cancer; 2019 Aug; 134():46-51. PubMed ID: 31319994
[TBL] [Abstract][Full Text] [Related]
11. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
Gordon MS; Mendelson DS; Gross M; Uttenreuther-Fischer M; Ould-Kaci M; Zhao Y; Stopfer P; Agus DB
Invest New Drugs; 2013 Apr; 31(2):409-16. PubMed ID: 23242861
[TBL] [Abstract][Full Text] [Related]
12. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring
Ko R; Shukuya T; Imamura CK; Tokito T; Shimada N; Koyama R; Yamada K; Ishii H; Azuma K; Takahashi K
Transl Lung Cancer Res; 2021 Jan; 10(1):183-192. PubMed ID: 33569303
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
[TBL] [Abstract][Full Text] [Related]
16. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.
Bahleda R; Varga A; Bergé Y; Soria JC; Schnell D; Tschoepe I; Uttenreuther-Fischer M; Delord JP
Br J Cancer; 2018 Feb; 118(3):344-352. PubMed ID: 29337963
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
[TBL] [Abstract][Full Text] [Related]
18. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
19. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
Keating GM
Drugs; 2014 Feb; 74(2):207-21. PubMed ID: 24435321
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Kim TM; Lee KW; Oh DY; Lee JS; Im SA; Kim DW; Han SW; Kim YJ; Kim TY; Kim JH; Han H; Kim WH; Bang YJ
Cancer Res Treat; 2018 Jul; 50(3):835-842. PubMed ID: 28859471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]